
Please try another search
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
John L. Brooks | 74 | - | Independent Director |
John Hathaway | 52 | - | Independent Director |
Scott F. Sneddon | 62 | - | CEO, Chief Science Officer & Director |
Lorne Michael Sugarman | 55 | - | Independent Director & Corporate Secretary |
Dietrich A. Stephan | 55 | - | INdependent Director |
William R. Newlin | 85 | - | Independent Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review